Drug Combination Improves Survival in Pancreatic Cancer
Links shared publicly online about this topic.
- 955total visits
Drug Combination Improves Survival in Pancreatic Cancer
View full resource at clinicaloncology.com
Tags: Pancreatic Disease, Cancer, Cancer Medication, Pancreatic Cancer, Drug, Gemzar, Eli Lilly and Company
Most Recently Shared on August 11, 2010 at 9:55 pm By:
Drug Combination Improves Survival in Pancreatic Cancer http://ow.ly/2ojbt
Aveo says cancer drug not better than existing therapy | Reuters
reuters.com — “(Reuters) - Aveo Pharmaceuticals Inc said a combination of its experimental drug to treat a type of lung cancer and the standard of care did not significantly improve the response and survival rate in” View full resource at reuters.com
Most Recently Shared on May 2, 2012 at 12:43 pm By:
Aveo says cancer drug not better than existing therapy http://t.co/paaFftH3
Aveo says cancer drug not better than existing therapy | Reuters
in.reuters.com — “(Reuters) - Aveo Pharmaceuticals Inc said a combination of its experimental drug to treat a type of lung cancer and the standard of care did not significantly improve the response and survival rate in” View full resource at in.reuters.com
Most Recently Shared on May 2, 2012 at 12:31 pm By:
Aveo says cancer drug not better than existing therapy http://t.co/Kx6pIcHS
Cabazitaxel with IMRT, androgen deprivation therapy may extend survival for prostate cancer patients
news-medical.net — “Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients.” View full resource at news-medical.net
Most Recently Shared on January 13, 2012 at 9:28 am By:
john clay mchugh Surgeon, Urologist, Physician, and Doctor
Cabazitaxel with IMRT, androgen deprivation therapy may extend survival for prostate cancer patients: Jefferson'... http://t.co/y7uUj2MD
Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
medicalxpress.com — “Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually ...” View full resource at medicalxpress.com
Most Recently Shared on January 12, 2012 at 5:29 pm By:
Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival http://t.co/vKvoOm9X
FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News
oralcancernews.org — “FDA Approves Cetuximab for Metastatic Head and Neck Cancer | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on November 8, 2011 at 2:00 pm By:
Novartis’s Afinitor helps Pfizer’s Aromasin to Delay Breast Cancer | The Haystack
cenblog.org — “Looks like Afinitor (everolimus), a drug marketed by Novartis for various cancers, may soon have a new indication. Already approved for a variety of diseases – kidney cancer, pancreatic tumors, and organ rejection prevention – Afinitor shows new promise for breast cancer patients. Clinical data released Monday demonstrate marked improvement for hormone-resistant breast cancer patients [...]” View full resource at cenblog.org
Most Recently Shared on September 28, 2011 at 2:23 pm By:
When Afinitor, an mTOR inhibitor, is used in combination with the aromatase inhibitor Aromasin, good things happen http://t.co/CPulkAU5
Symposier - Dr. Chabot Discusses Pancreatic Cancer Chemotherapy
symposier.com — “Uploaded and shared in Youtube by: OncLiveTV — John Chabot, MD, chief, division of GI/Endocrine Surgery, executive director, Pancreas Center at New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, discusses the current chemotherapy options available to treat pancreatic cancer. The main drug available is gemcitabine and is currently used in combination therapies. There are currently trials underway that are demonstrating improved survival with aggressive chemotherapy.” View full resource at symposier.com
Most Recently Shared on August 30, 2011 at 5:24 pm By:
Symposier Endocrino Health Site
Dr. Chabot Discusses Pancreatic Cancer Chemotherapy. http://t.co/EAJX9HR
Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced Pancreatic Cancer - MPR
empr.com — “Data from the BAYPAN study presented at the American College of Clinical Oncology’s 2011 Annual Meeting did not support the addition of sorafenib to gemcitabine therapy in the treatment of advanced pancreatic cancer (APC), in contrast to an earlier Phase I study that demonstrated that this combination was well tolerated and had activity in APC patients.” View full resource at empr.com
Most Recently Shared on June 6, 2011 at 9:01 pm By:
#asco2011 Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced… http://goo.gl/fb/XYOKi
Vaccine first to show improved survival rates for metastatic melanoma
labspaces.net — “For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.” View full resource at labspaces.net
Most Recently Shared on June 6, 2011 at 1:15 pm By:
Vaccine first to show improved survival rates for metastatic melanoma - http://is.gd/AR64mY
Survival Rates For Metastatic Melanoma Improve With Immune-boosting Interleukin-2 Vaccine
medicalnewstoday.com — “For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 ca” View full resource at medicalnewstoday.com
Most Recently Shared on June 5, 2011 at 7:05 am By:
Survival Rates For Metastatic Melanoma Improve With Immune-boosting Interleukin-2 Vaccine http://mnt.to/3WLG #skincancer #melanoma
Vaccine First To Show Improved Survival Rates For Metastatic Melanoma
medicalnewstoday.com — “For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 ca” View full resource at medicalnewstoday.com
Most Recently Shared on June 5, 2011 at 5:52 am By:
Vaccine First To Show Improved Survival Rates For Metastatic Melanoma: For patients with advanced melanoma, whic... http://bit.ly/j6MXa4
Vaccine First to Show Improved Survival Rates for Metastatic Melanoma
newswise.com — “For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2can improve response rate and progression-free survival.” View full resource at newswise.com
Most Recently Shared on June 3, 2011 at 9:01 pm By:
#health news: Vaccine First to Show Improved Survival Rates for Metastatic Melanoma: For patients with advanced ... http://bit.ly/kVz7nd
Vaccine First to Show Improved Survival Rates for Metastatic Melanoma
newswise.com — “For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2can improve response rate and progression-free survival.” View full resource at newswise.com
Most Recently Shared on June 3, 2011 at 8:22 pm By:
newswise Health Communicator and Health News
Vaccine First to Show Improved Survival Rates for Metastatic Melanoma: For patients with advanced melanoma, whic... http://bit.ly/jbtdHy
Therapeutic Melanoma Vaccine Improves Response Rate, Progression-Free Survival - QualityPoint Technologies
qualitypointtech.net — “A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care. The findings, published in the June 2 New England Journal of Medicine, mark the first vaccine study in the disease - and one of the first in cancer over” View full resource at qualitypointtech.net
Most Recently Shared on June 2, 2011 at 9:00 am By:
Therapeutic Melanoma Vaccine Improves Response Rate, Progression-Free Survival: A vaccine for one of the most leth... http://bit.ly/jWrehL
Therapeutic Melanoma Vaccine Improves Response Rate, Progression-Free Survival
medicalnewstoday.com — “A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, acco” View full resource at medicalnewstoday.com
Most Recently Shared on June 2, 2011 at 7:05 am By:
Therapeutic Melanoma Vaccine Improves Response Rate, Progression-Free Survival http://mnt.to/3WDc #skincancer #melanoma
Advertisement
